Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2026)
Alnylam Pharmaceuticals (ALNY) reported EPS (Weighted Average and Diluted) of $1.51 for Q1 2026, up 1178.57% on a YoY basis from $0.12 in Q1 2025, and up 84.15% quarter-over-quarter from $0.82 in Q4 2025.
Alnylam Pharmaceuticals (ALNY) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported EPS (Weighted Average and Diluted) for 8 years, with the latest figure at $1.51 in Q1 2026.
- For the quarter ending Q1 2026, EPS (Weighted Average and Diluted) rose 1178.57% year-over-year to $1.51; the trailing twelve-month figure through Mar 2026 stood at $3.66 (up 304.47% YoY), and the FY2025 full-year result was $2.33, up 206.88% from the prior year.
- EPS (Weighted Average and Diluted) for Q1 2026 stood at $1.51, up from $0.82 in the prior quarter.
- The five-year high for EPS (Weighted Average and Diluted) was $1.84 in Q3 2025, with the low at -$3.32 in Q3 2022.
- Historically, EPS (Weighted Average and Diluted) has averaged -$0.68 across 5 years, with a median of -$0.65 in 2024.
- Annual changes were most pronounced in 2025 — EPS (Weighted Average and Diluted) tumbled 292.31% — and 2026, when it jumped 1178.57%.
- Alnylam Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$1.68 in 2022, then soared by 35.12% to -$1.09 in 2023, then jumped by 40.37% to -$0.65 in 2024, then surged by 226.15% to $0.82 in 2025, then surged by 84.15% to $1.51 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at $1.51 (Q1 2026), $0.82 (Q4 2025), and $1.84 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 1.51 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.51 |
| Dec 31, 2025 | 0.82 |
| Sep 30, 2025 | 1.84 |
| Jun 30, 2025 | -0.51 |
| Mar 31, 2025 | -0.14 |
| Dec 31, 2024 | -0.65 |
| Sep 30, 2024 | -0.87 |
| Jun 30, 2024 | -0.13 |
| Mar 31, 2024 | -0.52 |
| Dec 31, 2023 | -1.09 |
| Sep 30, 2023 | 1.15 |
| Jun 30, 2023 | -2.21 |
| Mar 31, 2023 | -1.40 |
| Dec 31, 2022 | -1.68 |
| Sep 30, 2022 | -3.32 |
| Jun 30, 2022 | -2.29 |
| Mar 31, 2022 | -2.00 |
| Dec 31, 2021 | -2.16 |
| Sep 30, 2021 | -1.72 |
| Jun 30, 2021 | -1.61 |